tetano
Editor, Senior Moderator
Rev Esp Quimioter. 2017 Feb 8. pii: reina08feb2017. [Epub ahead of print]
[h=1][Favipiravir, a new concept of antiviral drug against influenza viruses].[/h] [Article in Spanish]
Reina J[SUP]1[/SUP], Reina N.
[h=3]Author information[/h]
[h=3]Abstract[/h] Favipiravir (T-705) is a new antiviral drug with strong inhibitory activity on RNA-dependent RNA polymerase of most RNA virus genome. All the influenza viruses have been shown fully sensitive to this new antiviral, including genetic strains to neuraminidase inhibitors (oseltamivir) resistance. Its mechanism of action lies in blocking viral replication and induction of lethal mutagenesis which determines the loss of infective activity of influenza viruses. Its activity is particularly intense in the respiratory tract, decreasing the viral load to non-infectious levels. Clinical trials in humans have not yet completed but have very favourable results. It seems that the best therapy would be the combination of favipiravir with oseltamivir; both antivirals are synergistic and avoid the emergence of resistance.
PMID: 28176519
[PubMed - as supplied by publisher]
[h=1][Favipiravir, a new concept of antiviral drug against influenza viruses].[/h] [Article in Spanish]
Reina J[SUP]1[/SUP], Reina N.
[h=3]Author information[/h]
[h=3]Abstract[/h] Favipiravir (T-705) is a new antiviral drug with strong inhibitory activity on RNA-dependent RNA polymerase of most RNA virus genome. All the influenza viruses have been shown fully sensitive to this new antiviral, including genetic strains to neuraminidase inhibitors (oseltamivir) resistance. Its mechanism of action lies in blocking viral replication and induction of lethal mutagenesis which determines the loss of infective activity of influenza viruses. Its activity is particularly intense in the respiratory tract, decreasing the viral load to non-infectious levels. Clinical trials in humans have not yet completed but have very favourable results. It seems that the best therapy would be the combination of favipiravir with oseltamivir; both antivirals are synergistic and avoid the emergence of resistance.
PMID: 28176519
[PubMed - as supplied by publisher]